Distribution of genital wart human papillomavirus genotypes in China: A multi-center study

Journal of Medical Virology

Volumn 85, Issue 10, 2013, Pages 1765-1774

  Chang, Lihong ^a   Ci, Puwa ^b,c   Shi, Jufang ^b   Zhai, Kan ^a   Feng, Xiaoli ^b   Colombara, Danny ^d   Wang, Wei ^e   Qiao, Youlin ^b   Chen, Wen ^b   Wu, Yuping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Global Medical Affairs Merck Sharp Dohme China   (China)

Author keywords

China; Distribution; Genital warts; HPV genotypes; Human papillomavirus

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHINA; CONDYLOMA ACUMINATUM; EDUCATION; FEMALE; GENETIC RISK; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MIXED INFECTION; OCCUPATION; POLYMERASE CHAIN REACTION; PREVALENCE; RURAL AREA; SEQUENCE ANALYSIS; SEX DIFFERENCE; TREND STUDY; URBAN AREA; VIRUS GENE; WART VIRUS;

CHINA; DISTRIBUTION; GENITAL WARTS; HPV GENOTYPES; HUMAN PAPILLOMAVIRUS;

ADOLESCENT; ADULT; AGED; CHINA; CONDYLOMATA ACUMINATA; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; PAPILLOMAVIRIDAE; PREVALENCE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84881029715     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23646     Document Type: Article

References (47)

1. Anic GM, Lee JH, Stockwell H, Rollison DE, Wu Y, Papenfuss MR, Villa LL, Lazcano-Ponce E, Gage C, Silva RJ, Baggio ML, Quiterio M, Salmeron J, Abrahamsen M, Giuliano AR. 2011. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: The HPV in men study. J Infect Dis 204:1886-1892.
2. Arima Y, Winer RL, Feng Q, Hughes JP, Lee SK, Stern ME, O'Reilly SF, Koutsky LA. 2010. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis 202:1181-1184.
3. Aubin F, Pretet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D. 2008. Human papillomavirus genotype distribution in external acuminata condylomata: A Large French National Study (EDiTH IV). Clin Infect Dis 47:610-615.
4. Ault KA. 2007. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 369:1861-1868.
5. Ball SL, Winder DM, Vaughan K, Hanna N, Levy J, Sterling JC, Stanley MA, Goon PK. 2011. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol 83:1345-1350.
6. Barr E, Tamms G. 2007. Quadrivalent human papillomavirus vaccine. Clin Infect Dis 45:607-609.
7. Bernard HU. 2005. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 32:S1-S6.
8. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26:K1-K16.
9. Brown DR, Bryan JT, Cramer H, Katz BP, Handy V, Fife KH. 1994. Detection of multiple human papillomavirus types in condylomata acuminata from immunosuppressed patients. J Infect Dis 170:759-765.
10. Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, Chen JF, Legood R, Smith MA, Nickson C, Qiao YL. 2011. Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 29:2487-2494.
11. Cremin S, Menton JF, Canier L, Horgan M, Fanning LJ. 2012. The prevalence and genotype of human papillomavirus on cervical samples from an Irish female population with external genital warts. Hum Vaccin Immunother 8:916-920.
12. Dalstein V, Riethmuller D, Sautiere JL, Pretet JL, Kantelip B, Schaal JP, Mougin C. 2004. Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 40:1225-1232.
13. de Roda HA, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. 1995. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76:1057-1062.
14. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 7:453-459.
15. Dunne EF, Markowitz LE. 2006. Genital human papillomavirus infection. Clin Infect Dis 43:624-629.
16. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917.
17. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928-1943.
18. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. 2009. Natural history of genital warts: Analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 199:805-814.
19. Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M. 2003. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 12:477-484.
20. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. 2000. Improved amplification of genital human papillomaviruses. J Clin Microbiol 38:357-361.
21. Hamlin-Douglas LK, Coutlee F, Roger M, Franco EL, Brassard P. 2008. Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiol Biomarkers Prev 17:3141-3149.
22. IARC. 2006. Monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. Lyons: International Agency for Research on Cancer 90.
23. Jaberipour M, Momtahan M, Najib F, Amooei S, Saidifard F, Ghaderi A, Habibagahi M. 2011. Detection of high-risk human papillomavirus types 16 and 18 but not 33 and 52 in external genital warts from Iranian females. Asian Pac J Cancer Prev 12:771-774.
24. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. 1997. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35:791-795.
25. Jamshidi M, Shekari M, Nejatizadeh AA, Malekzadeh K, Baghershiroodi M, Davudian P, Dehghan F, Jamshidi F. 2012. The impact of human papillomavirus (HPV) types 6, 11 in women with genital warts. Arch Gynecol Obstet. 286:1261-1267.
26. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. 2007. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 369:1693-1702.
27. Komlos KF, Kocjan BJ, Kosorok P, Luzar B, Meglic L, Potocnik M, Hocevar-Boltezar I, Gale N, Seme K, Poljak M. 2012. Tumor-specific and gender-specific pre-vaccination distribution of human papillomavirus types 6 and 11 in anogenital warts and laryngeal papillomas: A study on 574 tissue specimens. J Med Virol 84:1233-1241.
28. Koshiol JE, Laurent SA, Pimenta JM. 2004. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 31:748-752.
29. Lefevre J, Hankins C, Pourreaux K, Voyer H, Coutlee F. 2003. Real-time PCR assays using internal controls for quantitation of HPV-16 and beta-globin DNA in cervicovaginal lavages. J Virol Methods 114:135-144.
30. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. 2004. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278-285.
31. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
32. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM. 2009. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 5:696-704.
33. Potocnik M, Kocjan BJ, Seme K, Poljak M. 2007. Distribution of human papillomavirus (HPV) genotypes in genital warts from males in Slovenia. Acta Dermatovenerol Alp Panonica Adriat 16:91-96; 98.
34. Pretet JL, Jacquard AC, Carcopino X, Charlot JF, Bouhour D, Kantelip B, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D. 2008. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer 122:428-432.
35. Sambrook J, Russell DW. 2001. Molecular cloning: A laboratory manual. 3rd edition. Cold Spring Harbor Laboratory Press. pp 467-470.
36. Schiffman M, Castle PE. 2003. Human papillomavirus: Epidemiology and public health. Arch Pathol Lab Med 127:930-934.
37. Shi JF, Kang DJ, Qi SZ, Wu HY, Liu YC, Sun LJ, Li L, Yang Y, Li Q, Feng XX, Zhang LQ, Li J, Li XL, Yang Y, Niyazi M, Xu AD, Liu JH, Xiao Q, Li LK, Wang XZ, Qiao YL. 2012. Impact of genital warts on health related quality of life in men and women in mainland China: A multicenter hospital-based cross-sectional study. Bmc Public Health 12:153.
38. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, Kong HJ, Rha SH, Jung SI, Kim JI, Jung KY, van Doorn LJ, Quint W. 2004. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 190:468-476.
39. Strauss MJ, Khanna V, Koenig JD, Downs SM, Goldberg SH, Manyak MJ, Patsner B. 1996. The cost of treating genital warts. Int J Dermatol 35:340-348.
40. Tian ZQ, Liu JF, Zhang SW, Li BQ, Wang FS, Zhang YF. 2004. A study on the method of DNA extraction from unbuffered formalin-fixed and paraffin-embedded samples. Ai Zheng 23:342-435.
41. Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ. 2005. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: Infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 192:2099-2107.
42. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278.
43. Wang H, Qiao YL. 2008. Human papillomavirus type-distribution in condylomata acuminata of mainland China: A meta-analysis. Int J Std Aids 19:680-684.
44. Wang SM, Shi JF, Kang DJ, Song P, Qiao YL. 2011. Impact of human papillomavirus-related lesions on quality of life: A multicenter hospital-based study of women in mainland China. Int J Gynecol Cancer 21:182-188.
45. Wu Y, Chen Y, Li L, Yu G, He Y, Zhang Y. 2006. Analysis of mutations in the E6/E7 oncogenes and L1 gene of human papillomavirus 16 cervical cancer isolates from China. J Gen Virol 87:1181-1188.
46. Xia YZ, Zhang CG, Chen YY, Sheng Y, Sun H. 2007. Discussing on the feasibility of large fragments DNA extraction from formalin-fixed fish specimens. Acta Hydrobiologica Sinica 31:485-491.
47. Yun K, Joblin L. 1993. Presence of human papillomavirus DNA in condylomata acuminata in children and adolescents. Pathology 25:1-3.